Caribou Biosciences, Inc.
NASDAQ:CRBUBiotechnology
-$0.05 today
- Market cap
- $52.47M
- Beta
- 2.33
- P/E (TTM)
- -1.1
- EPS (TTM)
- -$1.39
Volume 1.01M
Average 1.83M
CRBU EBITDA Margin
EBITDA as a percentage of revenue.
Caribou Biosciences, Inc.NASDAQ: CRBU
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -1019.4%
EBITDA Margin was -1019.4% in Q1 FY2026, up 630.6 pp from a year earlier. On a trailing-twelve-month basis it was -999.5%, up 475.3 pp year over year. Over 3 fiscal years it narrowed by 608.7 pp.
Context
- EBITDA Margin widened in 2 of the last 3 fiscal years.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 4 analysts of -914.4% for the fiscal year ending Dec 2026, up from -1299.7% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -1019.4%-350.7 pp QoQ
- Last fiscal yearDec 2025
- -1299.7%+153.1 pp YoY
- LTMMar 2026
- -999.5%+475.3 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -1299.7%
- Year-over-year change
- +153.1pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -1299.7% | +153.1pp |
| FY2024 | 2024-12-31 | -1452.7% | -1167.5pp |
| FY2023 | 2023-12-31 | -285.3% | +405.7pp |
| FY2022 | 2022-12-31 | -691.0% | -7.4pp |
| FY2021 | 2021-12-31 | -683.6% | — |
EBITDA Margin vs competitors
How CRBU compares with its peers on the latest reported figures
- CRBU's LTM Mar 2026 EBITDA Margin of -999.5% is the 6th highest of the 9 companies compared; the peer median is -501.6%.
- Its year-over-year change of +475.3 pp is the 3rd highest of 7, against a peer median of +72.6 pp.
- Over three fiscal years its change of -608.7 pp compares with a peer median of +30.0 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | -67.3% | +67.9 pp | +30.0 pp | |
| LTM Mar 2026 | -161.1% | +2125.8 pp | +792.0 pp | |
| LTM Mar 2026 | -257.0% | +77.3 pp | +319.4 pp | |
| LTM Mar 2026 | -455.3% | +1345.3 pp | — | |
| LTM Mar 2026 | -547.9% | — | — | |
| LTM Mar 2026 | -999.5% | +475.3 pp | -608.7 pp | |
| FY2025 | -2858.6% | -1048.1 pp | -2396.4 pp | |
| LTM Mar 2026 | -3956.7% | -3182.9 pp | -1247.4 pp | |
| LTM Mar 2026 | -33540.9% | — | — | |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding CRBU) | -501.6% | +72.6 pp | +30.0 pp | |
Competitors are the stored peer set for CRBU. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 9.6M | 13.85M | 34.48M | 9.99M | 11.16M |
| Cost of Revenue | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| Gross Profit | 8.61M | 10.21M | 30.95M | 6.07M | 7.51M |
| Gross Margin | 89.7% | 73.7% | 89.8% | 60.7% | 67.3% |
| Research & Development | 52.26M | 82.23M | 112.08M | 130.15M | 109.44M |
| Selling, General & Admin | 23.34M | 38.02M | 38.46M | 46.46M | 37.91M |
| Operating Expenses | 75.59M | 116.61M | 147.01M | 172.68M | 143.71M |
| Depreciation & Amortization | 984K | 3.64M | 3.53M | 3.93M | 3.65M |
| EBITDA | (65.61M) | (95.71M) | (98.35M) | (145.19M) | (145.03M) |
| EBITDA Margin | -683.6% | -691.0% | -285.3% | -1452.7% | -1299.7% |
| Operating Income | (66.98M) | (106.4M) | (116.06M) | (166.62M) | (136.19M) |
| Operating Margin | -697.8% | -768.2% | -336.6% | -1667.2% | -1220.5% |
| Interest Income | 148K | 4.6M | 10.7M | 0 | 8M |
| Interest Expense | 8K | 0 | 0 | 0 | 0 |
| Other Income / Expenses | 377K | 7.05M | 14.18M | 17.5M | (12.48M) |
| Income Before Tax | (66.6M) | (99.35M) | (101.88M) | (149.11M) | (148.68M) |
| Pre-Tax Margin | -693.9% | -717.3% | -295.5% | -1492.0% | -1332.3% |
| Income Tax Expense | 321K | 70K | 193K | (9K) | (550K) |
| Net Income | (66.92M) | (99.42M) | (102.07M) | (149.11M) | (148.13M) |
| Net Margin | -697.3% | -717.8% | -296.1% | -1491.9% | -1327.4% |
| EPS (Basic) | (1.11) | (1.64) | (1.38) | (1.65) | (1.59) |
| EPS (Diluted) | (1.11) | (1.64) | (1.38) | (1.65) | (1.59) |
| Weighted Avg Shares | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M |
| Weighted Avg Shares (Diluted) | 60.26M | 60.8M | 73.81M | 90.32M | 93.39M |
Caribou Biosciences, Inc.
NASDAQ:CRBU
Intrinsic Alpha fair value
Locked
Current Price
$0.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.